Prin­cip­ia, Ab­b­Vie walk away from 2017 part­ner­ship for in­flam­ma­to­ry, au­toim­mune drugs

San Fran­cis­co-based Prin­cip­ia and part­ner Ab­b­Vie have elect­ed to part ways on a col­lab­o­ra­tion they signed about two years ago, which hand­ed the new­ly pub­lic biotech $15 mil­lion up­front.

The drug de­vel­op­er, run by a troop of ex­ec­u­tives drawn from Roche, joined forces with Ab­b­Vie in June 2017 to de­vel­op oral im­muno­pro­tea­some in­hibitors for in­flam­ma­to­ry and au­toim­mune dis­or­ders. Im­muno­pro­tea­some is a fam­i­ly of pro­tea­some — the cell’s pro­tein re­cy­clers — found abun­dant­ly in im­mune cells, which play a role in im­mune re­spons­es, af­fect­ing anti­gen pre­sen­ta­tion, T cell func­tion and cy­tokine pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER